[18f]f-psma-n5
PeptideexperimentalImaging agent
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 10, 2024 (NCT06462495)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Glutamate carboxypeptidase IIRadiopharmaceutical
FOLH1 radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06935149 | Phase 1 | May 1, 2025 | Kaohsiung Medical University, Primo Biotechnology Co., Ltd |
| NCT06756334 | Early Phase 1 (Phase 1) | Dec 19, 2024 | Anhui Medical University |
| NCT06462508 | Early Phase 1 (Phase 1) | Apr 20, 2024 | Anhui Medical University, Anhui Province Cancer Hospital |
| NCT06462495 | Early Phase 1 (Phase 1) | Apr 10, 2024 | Anhui Medical University, Anhui Province Cancer Hospital |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Anhui Medical University | Academic/Hospital | 3 | 3 | 1 | 2024 |
| Anhui Province Cancer Hospital | Academic/Hospital | 2 | 0 | 1 | 2024 |
| Kaohsiung Medical University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Primo Biotechnology Co., Ltd | For profit | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1